Kerala Ayurveda Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Kerala Ayurveda's earnings have been declining at an average annual rate of -37.8%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 16.9% per year.
Key information
-37.8%
Earnings growth rate
-33.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 16.9% |
| Return on equity | -12.0% |
| Net Margin | -1.4% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Kerala Ayurveda makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1,007 | -14 | 395 | 0 |
| 30 Jun 23 | 984 | -4 | 372 | 0 |
| 31 Mar 23 | 936 | -9 | 364 | 0 |
| 31 Dec 22 | 927 | -4 | 357 | 0 |
| 30 Sep 22 | 869 | 28 | 299 | 0 |
| 30 Jun 22 | 788 | 12 | 233 | 0 |
| 31 Mar 22 | 804 | 24 | 282 | 0 |
| 31 Dec 21 | 757 | -14 | 292 | 0 |
| 30 Sep 21 | 726 | -35 | 288 | 0 |
| 30 Jun 21 | 650 | -43 | 239 | 0 |
| 31 Mar 21 | 621 | -48 | 265 | 0 |
| 31 Dec 20 | 645 | -16 | 270 | 0 |
| 30 Sep 20 | 668 | -7 | 272 | 0 |
| 30 Jun 20 | 674 | 25 | 230 | 0 |
| 31 Mar 20 | 768 | 39 | 300 | 0 |
| 31 Dec 19 | 726 | 47 | 272 | 0 |
| 30 Sep 19 | 692 | 47 | 266 | 0 |
| 30 Jun 19 | 610 | 33 | 216 | 0 |
| 31 Mar 19 | 622 | 24 | 249 | 0 |
| 31 Mar 18 | 589 | 28 | 217 | 0 |
| 31 Mar 17 | 504 | 31 | 188 | 0 |
| 31 Mar 16 | 459 | 27 | 168 | 0 |
| 31 Mar 15 | 390 | 24 | 149 | 0 |
| 31 Mar 14 | 349 | 7 | 219 | 0 |
Quality Earnings: 530163 is currently unprofitable.
Growing Profit Margin: 530163 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 530163 is unprofitable, and losses have increased over the past 5 years at a rate of 37.8% per year.
Accelerating Growth: Unable to compare 530163's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 530163 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: 530163 has a negative Return on Equity (-12.03%), as it is currently unprofitable.